Eli Lilly CFO on $1 Billion AI Drug Lab Investment

Summary

Eli Lilly CFO Lucas Montarce discusses the company's obesity-drug pipeline, including expected approval of its obesity pill as early as Q2 and the QuickPen device within months. He highlights Medicare access starting as early as April, Lilly's active M&A pipeline, multiple oncology/neuroscience/immunology catalysts, and a new $1 billion AI drug-discovery collaboration with Nvidia.

• Eli Lilly expects US approval for its obesity pill as early as Q2.
• QuickPen device approval is expected within the next few months.
• Medicare obesity coverage could begin April to July with $50 patient payments.
• Lilly signed more than 50 M&A deals last year, focused on early-phase assets.
• Pipeline catalysts are expected in oncology, neurodegeneration, and immunology.
• Lilly and Nvidia announced a five-year AI lab collaboration with up to $1 billion investment.
• Management is not targeting specific operating margins and prioritizes reinvestment for sustainable growth.